Skip to main content
. 2024 Oct 27;60(11):1763. doi: 10.3390/medicina60111763

Table 1.

Descriptive statistics of demographics and clinical characteristics for the study cohort stratified according to European Association of Urology (EAU) prognostic risk categories.

EAU Low-Risk PCa
n = 297 (28.4%)
EAU Intermediate-Risk PCa
n = 527 (50.3%)
EAU High-Risk PCa
n = 223 (21.3%)
p-Value
Age (years) 65.2 (59.3–69.7) 65.2 (60.1–70.2) 67.7 (61.1–71.2) 0.036
BMI (kg/m2) 26.1 (23.9–28.4) 25.6 (23.7–27.8) 25.7 (24.2–28.4) 0.039
ASA physical status 0.1
 ASA I 25 (8.4) 47 (8.9) 16 (7.2)
 ASA II 253 (85.2) 427 (81.0) 178 (79.8)
 ASA III 19 (6.4) 53 (10.1) 29 (13.0)
PV (mL) 40 (30–50) 38 (30–49) 40 (30–55) 0.042
PSA (ng/mL) <0.001
 <10 297 (100) 421 (79.9) 126 (56.5)
 10–20 0 (0) 106 (20.1) 47 (21.1)
 >20 0 (0) 0 (0) 50 (22.4)
BPC (%) 26.6 (14.2–41.6) 28.5 (18.7–47.0) 42.8 (26.6–62.5) <0.001
Clinical T stage <0.001
 T1c 225 (75.8) 304 (57.7) 71 (31.8)
 T2 72 (24.2) 223 (42.3) 116 (52.0)
 T3 0 (0) 0 (0) 36 (16.2)
ISUP grade group <0.001
 ISUP 1 297 (100) 35 (6.6) 29 (13.0)
 ISUP 2–3 0 (0) 492 (93.4) 62 (27.8)
 ISUP 4–5 0 (0) 0 (0) 132 (59.2)
Clinical N stage <0.001
 N0 297 (100) 527 (100) 166 (74.4)
 N1 0 (0) 0 (0) 57 (25.6)
ePLND performed <0.001
 No 207 (69.7) 155 (29.4) 19 (8.5)
 Yes 90 (30.3) 372 (70.6) 204 (91.5)
2012 Briganti nomogram score (%) 2 (1–3) 3 (2–7) 12 (5–22) <0.001

Continuous variables are reported as medians (interquartile ranges) while categorical factors are reported as frequencies (percentages). Abbreviations: PCa, prostate cancer; BMI, body mass index; ASA, American Society of Anesthesiologists; PV, prostate volume; PSA, prostate-specific antigen; BPC, biopsy positive cores; ISUP, International Society of Urological Pathology; ePLND, extended pelvic lymph node dissection. Values in bold indicate statistical significance set at p < 0.05.